PCOS (Polycystic Ovary Syndrome)PCOS patientsNCT07112768
LH/FSH, Testosterone, Prolactin, and Ferritin in PCOS Patients in Jordan
An observational study of PCOS (Polycystic Ovary Syndrome), run by Future University in Egypt at 1 site in Jordan.
Trial summary
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Read more about this study
- Who is it for?
- Ages 20 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- PCOS (Polycystic Ovary Syndrome)
- What is being tested?
- Serum levels of LH, FSH, testosterone, prolactin, and ferritin
- How many people
- 140 participants
- Where
- 1 siteJordan
- Study dates
- 2 Jan 2024to 22 Apr 2024
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: (n=140) females were included in the current study which were subdivided into two groups: the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist ; and the control group (n=60), consistening control women aged 22-41
Who may be able to join
- Age 20-45 PCOS diagnosed females Jordanian
Who cannot join
- younger than 20 older than 45 Non -Jordanian
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Role of LH/FSH, Testosterone, Prolactin, and Ferritin in PCOS Patients in Jordan
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Despite its widespread occurrence, a comprehensive study particularly within the Jordanian population remains limited. Aim of the study: The study aimed to assess the serum levels of the Luteinizing hormone (LH), Follicle stimulating hormone (FSH), LH/FSH ratio, Testosterone, Prolactin, and Ferritin in Jordanian women diagnosed with PCOS
Read the detailed description
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Despite its widespread occurrence, a comprehensive study particularly within the Jordanian population remains limited. Aim of the study: The study aimed to assess the serum levels of the Luteinizing hormone (LH), Follicle stimulating hormone (FSH), LH/FSH ratio, Testosterone, Prolactin, and Ferritin in Jordanian women diagnosed with PCOS. Materials and Methods: A total 80 women aged between 20-41 years with confirmed PCOS diagnosis and 60 age matched healthy control were enrolled. Participant completed a structured questionnaire and provided informed consent .Blood samples were collected for measurement of LH, FSH, LH/FSH ratio, testosterone, prolactin, and ferritin levels using standardized laboratory protocol. Results: There were significant differences between the PCOS and control groups in the levels of LH, FSH, LH/FSH ratio, total testosterone, prolactin, and ferritin (p<0.05 for all). Specifically, the PCOS group showed higher levels of LH, testosterone, prolactin, and ferritin, while FSH levels were significantly lower. Additionally, positive correlations were observed between LH and testosterone, FSH and prolactin, and between ferritin and both LH and the LH/FSH ratio. Conclusions: The altered hormonal and biochemical profiles observed in PCOS patients emphasize the role of these biomarkers in diagnosing and understanding the pathophysiology of PCOS. These findings could support better clinical management and inform future research, particularly in the Jordanian patients.
- Conditions
- PCOS (Polycystic Ovary Syndrome)
- Being tested
- Serum levels of LH, FSH, testosterone, prolactin, and ferritin
- Medical subject headings
- Polycystic Ovary Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum levels of LH, FSH, testosterone, prolactin, and ferritinDiagnostic test
Also called LH, FSH, testosterone, prolactin, ferritin
Measurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin)
| Study group | Role | What they receive |
|---|---|---|
| Control group | control group (n=60), consisting control women aged 22-41 years Receives: Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritin | |
| PCOs group | the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist Receives: Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hormonal level
Serum levels of LH, FSH, testosterone, prolactin
Measured: 3 months
Biochemical marker
Serum level of Ferrtin
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2025
- Study start2 Jan 2024
- Primary completion10 Apr 2024
- Study completion22 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PCOS (Polycystic Ovary Syndrome)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 140 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Future University in Egypt
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Doaa Mohamed Salah ElDin Diab ELBohy, Al-Ahliyya Amman University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07112768
- Sponsor's protocol ID
- Al-Ahliyya Amman University 1
- Acronym
- PCOS patients
- Status last verified
- Aug 2025
- First submitted
- 2 Aug 2025
- Last updated
- 8 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The consent forms
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of LH/FSH, Testosterone, Prolactin, and Ferritin in PCOS Patients in Jordan
- ClinicalTrials.gov ID
- NCT07112768
- Acronym / sponsor ID
- PCOS patients / Al-Ahliyya Amman University 1
- Conditions
- PCOS (Polycystic Ovary Syndrome)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 140 participants (actual)
- Lead sponsor
- Future University in EgyptUniversity, hospital or other
- Study start
- 2 Jan 2024 (actual)
- Primary completion
- 10 Apr 2024 (actual)
- Study completion
- 22 Apr 2024 (actual)
- First posted
- 8 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Despite its widespread occurrence, a comprehensive study particularly within the Jordanian population remains limited. Aim of the study: The study aimed to assess the serum levels of the Luteinizing hormone (LH), Follicle stimulating hormone (FSH), LH/FSH ratio, Testosterone, Prolactin, and Ferritin in Jordanian women diagnosed with PCOS
Detailed description
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder impacting women of reproductive age. Characterized by chronic anovulation, hyperandrogenism, and the presence of multiple small ovarian cysts. Despite its widespread occurrence, a comprehensive study particularly within the Jordanian population remains limited. Aim of the study: The study aimed to assess the serum levels of the Luteinizing hormone (LH), Follicle stimulating hormone (FSH), LH/FSH ratio, Testosterone, Prolactin, and Ferritin in Jordanian women diagnosed with PCOS. Materials and Methods: A total 80 women aged between 20-41 years with confirmed PCOS diagnosis and 60 age matched healthy control were enrolled. Participant completed a structured questionnaire and provided informed consent .Blood samples were collected for measurement of LH, FSH, LH/FSH ratio, testosterone, prolactin, and ferritin levels using standardized laboratory protocol. Results: There were significant differences between the PCOS and control groups in the levels of LH, FSH, LH/FSH ratio, total testosterone, prolactin, and ferritin (p<0.05 for all). Specifically, the PCOS group showed higher levels of LH, testosterone, prolactin, and ferritin, while FSH levels were significantly lower. Additionally, positive correlations were observed between LH and testosterone, FSH and prolactin, and between ferritin and both LH and the LH/FSH ratio. Conclusions: The altered hormonal and biochemical profiles observed in PCOS patients emphasize the role of these biomarkers in diagnosing and understanding the pathophysiology of PCOS. These findings could support better clinical management and inform future research, particularly in the Jordanian patients.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control group | – | Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritincontrol group (n=60), consisting control women aged 22-41 years |
| PCOs group | – | Diagnostic Test: Serum levels of LH, FSH, testosterone, prolactin, and ferritinthe study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- (n=140) females were included in the current study which were subdivided into two groups: the study group (n=80), comprising women aged 20 to 41 years who were diagnosed with PCOS based on the Rotterdam criteria (2003) as assessed by obstetric and gynecology specialist ; and the control group (n=60), consistening control women aged 22-41
Key inclusion criteria (1 listed)
- Age 20-45 PCOS diagnosed females Jordanian
Key exclusion criteria (1 listed)
- younger than 20 older than 45 Non -Jordanian
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Serum levels of LH, FSH, testosterone, prolactin, and ferritinAlso: LH, FSH, testosterone, prolactin, ferritinMeasurement of both hormonal and biochemical markers in Jordanian PCOs females, including Serum levels of LH, FSH, testosterone, prolactin, and ferritin) | Diagnostic test | Control group, PCOs group |
Primary outcome
Hormonal level
Time frame: 3 months
Serum levels of LH, FSH, testosterone, prolactin
Biochemical marker
Time frame: 3 months
Serum level of Ferrtin
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2025.
- Individual participant dataSharing planned: Undecided. The consent forms
Related trials for PCOS (Polycystic Ovary Syndrome)
Recruiting
Efficacy of Ovarian Drilling Via vNOTES Laparoscopy in Patients With PCOS
PCOS (Polycystic Ovary Syndrome)
RecruitingPhase 1
Efficacy of Injectable Vitamin D Supplementation in Females With Polycystic Ovary Syndrome
Anovulatory Infertility
RecruitingObservational study
The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study
Polycystic Ovary Syndrome (PCOS)
Recruiting
The Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome
PCOS (Polycystic Ovary Syndrome)
Recruiting
Brown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography
Polycystic Ovary Syndrome (PCOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of PCOS (Polycystic Ovary Syndrome), run by Future University in Egypt at 1 site in Jordan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jordan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hormonal level (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.